Member Info for wheelerdealers

I’ve been a long-term supporter of FUM and continue to see significant value potential ahead. My approach has always been to reinvest only from realised gains (net of HMRC tax) — a disciplined strategy that has served me well over time. My last exit was around 48p, and I recently re-entered at 1.85p. I’m comfortable holding for the short- to medium-term, targeting the 6–10p range, with an anticipated £2.5 m …by early next year happy to share my personal view to help the disheartened

You are in best place . Zzzzz

FWIW

1. 🌿 Tacendo latet, loquendo lucet.

By silence it hides, by speech it shines.

2. ⚔️ Silentium stultis, verba sapientibus.

Silence is for fools, words are for the wise.

3. 🏛️ Loqui est philosophari.

To speak is to philosophize.

4 . “Responsum tuum veritate fundatum et contrarium, clara oratione pro omnibus lectoribus huius fori exspecto.”

Elegant English rendering:

“I await your opposing response, founded in truth and expressed with clarity, for the understanding of all readers in this forum.”

FWIW

Latin:

“Non tacuendo, sed eloquentia sapientiam ostendimus.”

Translation:

“Not by remaining silent, but through eloquence we display wisdom.”

FWIW

FIGURE

Non tacuere sapientiam servat, sed loqui notam veritatem manifestat.”

Oh do enlighten me as this is what I am here to share . Meanwhile I found from various public site the following rather than spouting . Let me make it clear here . I am happy to be corrected accurately when somebody wishes to share with their own facts . Here is what I reiterate .

Here’s what is known:

• Lombard Odier is recorded as the largest shareholder of Futura Medical, holding around 28% of the company’s shares outstanding. 

• There is a report that Lombard exercised options to buy near 11 million shares at a strike price of 40 pence each, putting roughly £4.3 million into Futura’s coffers via that option exercise.

Care to correct this fact . FWIW

In my humble opinion all shareholders should be encouraging the board

Members of the Board,

Futura Medical has reached a defining juncture in its journey — a point where scientific achievement, regulatory success, and market opportunity converge. The recent HY25 update, while candid about short-term commercial challenges, also reinforced a truth that long-term investors have always recognised: Futura’s innovation pipeline is robust, its global reach expanding, and its science validated.

This is not a moment for retreat but for renewed determination and leadership boldness.

We, as committed shareholders, respectfully urge the company to:

1. Reignite Futura’s Founding Vision

Re-articulate the company’s core mission to revolutionise sexual health through topical science. Inspire every team member to align with that purpose and communicate it clearly to partners, clinicians, and consumers worldwide.

2. Execute with Precision and Pace

Strengthen commercial execution and marketing strategies to convert regulatory progress into tangible sales growth. Pursue new partnerships and distribution networks that accelerate global rollout while protecting cash discipline.

3. Champion Gender-Inclusive Innovation

Position WSD4000 as the next frontier in female sexual wellness, building upon the proven credibility of Eroxon. This dual-category leadership can define Futura as a truly global health innovator.

4. Rebuild Market Confidence through Transparency and Accountability

Establish visible milestones and communicate progress regularly. Demonstrating consistent delivery will reinforce trust with both investors and commercial partners.

5. Lead with Conviction

The strength of Futura’s science and the support of its shareholders deserve leadership that communicates optimism, urgency, and clarity. Confidence is contagious — and it must start from the top.

Futura Medical possesses the rare combination of validated science, regulatory traction, and a vast untapped market. What it now requires is focused execution and unwavering belief — to transform potential into performance and reaffirm its status as a world-class British innovator in sexual health.

With sincerity and continued confidence,

Wheelerdealer

Let’s focus on company’s humbleness

Operational Highlights (Positive)

• Global Expansion:

Eroxon® has now been launched in 25 countries, marking a substantial increase in global reach and brand recognition.

• Regulatory Progress:

• Eroxon Intense, the enhanced formulation, remains on track for EU and U.S. regulatory approvals by end-2025, with strong consumer preference demonstrated in early studies.

• A Home User Study involving up to 200 UK participants has been commissioned to further validate its efficacy and market readiness.

• Advancement in Women’s Sexual Health Portfolio:

• Successful Home User Study on WSD4000 (for female sexual dysfunction) completed with positive results.

• The company held a pre-submission meeting with the U.S. FDA, paving the way for an Early Feasibility Study in Q1 2026.

• WSD4000 is positioned as a potentially first-in-class OTC treatment for impaired sexual response in women – a large, underserved global market.

• Product Validation:

Proof-of-concept work confirmed strong user preference for the enhanced sensorial effects of Eroxon Intense, reinforcing its differentiation and consumer appeal.

⸻

💷 Financial & Strategic Positives

• Despite reduced sales, half-year revenue of £1 million was maintained, with 50 % derived from U.S. royalties – demonstrating traction in the world’s largest healthcare market.

• Healthy gross profit (£0.73 m) before exceptional items reflects continued product profitability on a per-unit basis.

• The balance sheet remains stable, with £3.69 m cash at 30 June 2025 and active cost-control measures implemented to extend cash runway.

• The Board has initiated a strategic review to unlock shareholder value, exploring options such as additional partnerships, licensing, and distribution agreements across Eroxon, Eroxon Intense, and WSD4000.

⸻

💬 CEO’s Positive Outlook

Interim CEO Alex Duggan reaffirmed confidence in:

• Long-term global demand for topical products supporting male sexual health;

• The unique market opportunity for WSD4000 in women’s sexual wellness; and

• The inherent value of Futura’s technology, intellectual property, and formulation expertise in topical sexual-health products.

He emphasized that market development takes time, and the company is committed to a carefully planned, value-maximizing strategy benefiting shareholders, partners, and employees.

Don’t forget it’s cost Lombard around 40p to have acquired their stake of 28.1% . After taking into account at various stage in my humble opinion , as always do your own research and share anything different

In my humble opinion

Bear/Conservative

6 – 10 p

Minimal growth, steady UK/EU sales only

Base Case

18 – 26 p

Moderate adoption, profitable operations

Bull/Optimistic

35 – 50 p

Full U.S. rollout success + pipeline traction.

IN MY HUMBLE OPINION

The unique OTC topical ED gel gives Futura a differentiated proposition. If it proves successful in the marketplace, the company can capture part of the ED market with fewer direct competitors (since most ED treatments are prescription oral drugs).

• The global nature of the opportunity means that growth isn’t limited to one geography; a successful roll‐out in multiple markets could scale revenue materially.

• The investment in R&D and proprietary tech gives Futura more than just a single product: it has pipeline aspirations and optionality.

• Milestone payments and licensing deals mean that upside events (regulatory/patent approvals) become meaningful triggers.

• For value investors, a small company with many favourable attributes may present a “lottery ticket” style investment: high risk, but also high potential reward if execution is strong.

Of course DYR ON CAVIETS

Bull case (optimistic / best-case)

Assumptions:

• Major positive catalyst(s): U.S. patent granted early, milestone payment from partner realized on schedule, plus increased U.S. uptake meaning replenishment orders begin in earnest.

• Good marketing campaign works, awareness grows fast, maybe even over-performance in certain regions (Europe, Middle East, etc.).

• Pipeline products (Eroxon Intense, WSD4000 / SD4000) show strong regulatory progress or early market acceptance / preorders / approvals.

• Possibly another large partner or licensing deal that brings in either revenue or non-dilutive funding.

• Company manages cash well, perhaps reduces costs, keeps dilution minimal.

Potential in this case:

• Share price could increase by 5×, 10× or more from current low base, if investors reprice the stock for expected future high growth and pipeline value. Some forecast targets are extremely optimistic. For example some analyst price targets (maybe flawed or speculative) are £130 share price vs the current yo yo pence. 

What you need / what to watch

To try to capture the upside and reduce downside, you’d want to monitor / play:

• Patent grant status in U.S. The milestone payment is contingent on that. Delay or negative outcome puts pressure.

• Sales / refill / replenishment orders vs just initial stock / inventory orders. If sales beyond “first fill” are growing, that signals traction.

• Cash burn / cash runway and whether they announce any additional funding or partnerships. If cash drops too low without funding, risk of bankruptcy or heavy dilution.

• Marketing strategy changes especially around U.S. issues (like lockbox problems, awareness).

• Competitor actions (e.g. other OTC ED treatments, generics etc.), regulation, regulatory delays.

• Investor sentiment: this is small cap / AIM; news, warnings etc often swing share price a lot. News of revenue misses, patent delays, etc. will strongly move price.

It is inevitable SI services will be required, after all they have not sold their IT technology and they know how to run the business Long term buy

Don’t forget analyst have a target price of £1.80 based on current earnings

I think MCLS May have to accept tough terms by lenders , which may lead to price consolidation .
I would wait and see what are the deal terms before I plunge into investing in what is a fine business serving local community

Take a chill pill and rise to the occasion towards end of 2022.
Just read between the trading statement lines.
FUM will convert to FUN ??
Buy in any weakness as this are great opportunities thrown af investors

A massive thanks to latest uncertainties. I took advantage to top up in ISA just before close

Can you blame Andrew!
I am sure he will timely increase the rate.
How does Dec 2021 sound to you?

I couldn’t read the dividend payout on my mobile
Could someone mention it